Skip to main content
. Author manuscript; available in PMC: 2022 Mar 24.
Published in final edited form as: Br J Haematol. 2021 Feb 22;192(6):1054–1063. doi: 10.1111/bjh.17347

Figure 4.

Figure 4.

(A) Comparison of variant allelic fraction (VAF) of mutations in the setting of post-remission clonal hematopoiesis (CH) in the group with normalization of myeloid progenitors by multicolor flow cytometry (MFC), compared with those with preleukemic (PL) CD34+ cells. The median VAF of the most dominant mutation in the group with a PL immunophenotype was 0.31 (range 0.05—0.45) vs 0.07 (range 0.01–0.045) in the group with myeloid progenitors with normal immunophenotype (p=0.005). (B) The distribution of the most common mutations in the setting of post-remission CH between the MFC normal and MFC PL groups: SRSF2 and IDH2 mutations were exclusively seen in the PL group. (C) Comparison of VAF of DNMT3A and TET2 mutations between the PL and MFC normal groups. The VAF for DNMT3A mutations was significantly higher in the group with PL immunophenotype compared with the group with normal myeloid progenitors (0.28 vs 0.07, respectively; p=0.02) (D) There was no difference in relapse free survival between the FC normal and FC PL groups.